T
Timothy J Wilt
Researcher at University of Minnesota
Publications - 479
Citations - 41016
Timothy J Wilt is an academic researcher from University of Minnesota. The author has contributed to research in topics: Prostate cancer & Randomized controlled trial. The author has an hindex of 94, co-authored 457 publications receiving 36650 citations. Previous affiliations of Timothy J Wilt include Cochrane Collaboration & Agency for Healthcare Research and Quality.
Papers
More filters
Journal ArticleDOI
Fecal microbiota transplantation for clostridium difficile infection a systematic review
Dimitri Drekonja,Jon Reich,Selome Gezahegn,Nancy Greer,Aasma Shaukat,Roderick MacDonald,Indy Rutks,Timothy J Wilt +7 more
TL;DR: Fecal microbiota transplantation for Clostridium difficile infection (CDI) is increasingly used, primarily for recurrent CDI but also for refractory CDI and treatment of the initial CDI episode; among these, success rates were highly variable.
Journal ArticleDOI
Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia: A Systematic Review
TL;DR: The evidence suggests that S repens improves urologic symptoms and flow measures and was associated with fewer adverse treatment events in men with symptomatic benign prostatic hyperplasia.
Journal ArticleDOI
Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians
TL;DR: This guideline presents evidence-based recommendations on the benefits and harms of higher (<150 mm Hg) versus lower (140 mm HG) SBP targets for the treatment of hypertension in adults aged 60 years or older and graded the recommendations using the GRADE method.
Journal ArticleDOI
Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.
Mike Shelley,Timothy J Wilt,Jacquelyn Court,Bernadette Coles,Howard Kynaston,Malcolm David Mason +5 more
TL;DR: In a study from Amsterdam and Rome, the authors describe a phase I trial into the toxicity and safety of intravesical gemcitabine, and found that it was well tolerated with no systemic toxicity.
Journal ArticleDOI
Predictors and prevalence of erectile dysfunction in a racially diverse population.
TL;DR: The burden of ED on the US population is significant and obesity, hypertension, smoking, and diabetes mellitus are significantly associated with ED risk, and mitigation of these risk factors may ameliorate the burden ofED.